Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Country | Canada |
Founded | 2003 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 47 |
CEO | Joseph G. Oliveto M.B.A. |
Contact Details
Address: 1111 Boul. Dr.-frederik-philips, Ste 420 Montreal, A8 H4M 2X6 Quebec, Canada | |
Phone | (514) 336-0444 |
Website | milestonepharma.com |
Stock Details
Ticker Symbol | MIST |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001408443 |
CUSIP Number | 59935V107 |
ISIN Number | CA59935V1076 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Director |
Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor and Member of Scientific Advisory Board |
Jeff Nelson | Chief Operating Officer |
Kim Fox | Vice President of Communications |
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
Anita Holz | Vice President and Head of Medical Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 29, 2024 | 8-K | Current Report |
May 13, 2024 | 8-K | Current Report |
May 13, 2024 | 10-Q | Quarterly Report |
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 8, 2024 | 8-K | Current Report |
Mar 28, 2024 | 8-K | Current Report |
Mar 21, 2024 | 8-K | Current Report |
Mar 21, 2024 | 10-K | Annual Report |
Mar 4, 2024 | 8-K | Current Report |
Mar 1, 2024 | 424B5 | Filing |